USFDA1 Aug 2026, 03:01 pm
Zydus Lifesciences Receives USFDA EIR for Injectable Facility
AI Summary
Zydus Lifesciences Ltd announced it has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its injectable facility located at Zydus Biotech Park, Ahmedabad. The facility received a Voluntary Action Indicated (VAI) classification. The GMP surveillance inspection was conducted between April 27 and May 5, 2026. This development is significant as it pertains to a key manufacturing site for injectable products and indicates the facility's compliance with US FDA standards, paving the way for continued product approvals and market access in the US.
Key Highlights
- Zydus Lifesciences received USFDA Establishment Inspection Report (EIR).
- The report is for the company's injectable facility in Ahmedabad.
- The facility was classified as Voluntary Action Indicated (VAI).
- The inspection was a GMP surveillance conducted in April-May 2026.
- This signifies compliance with US FDA regulatory standards.
Price Impact
More from ZYDUSLIFE